5-MeO-DMT Is More Therapeutically Potent Than Psilocybin — And More Dangerous, Which Is Why Nobody Wants to Study It

5-MeO-DMT (the active compound in Bufo alvarius toad venom) produces the most intense mystical experiences of any psychedelic — but in minutes rather than hours. Survey data suggest single sessions produce sustained improvements in anxiety, depression, and PTSD symptoms (Davis et al., 2019, Psychopharmacology). The anecdotal clinical reports are extraordinary.

But 5-MeO-DMT is terrifying to study. The acute experience is overwhelming. There's no "guided therapy" — you're gone for 15-30 minutes. Cardiovascular effects are significant. The risk profile is different from psilocybin's gentle 6-hour journey. And yet — the mechanistic argument that intensity correlates with efficacy (if safely managed) has support.

Hypothesis: 5-MeO-DMT will prove to be the most therapeutically potent psychedelic, producing larger and more durable therapeutic effect sizes than psilocybin for treatment-resistant depression and PTSD — if safety protocols can be established. The intensity of ego dissolution, not the duration of the experience, is the key therapeutic variable.

Prediction: A Phase II trial of 5-MeO-DMT for treatment-resistant depression will show remission rates >50% (compared to ~30% for psilocybin in Compass Pathways' trial), with the ego dissolution intensity score being the strongest predictor of outcome.